Paula Ragan - Nov 15, 2024 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role: President and CEO, Director
Signature: /s/ Adam S. Mostafa, attorney-in-fact
Stock symbol: XFOR
Transactions as of: Nov 15, 2024
Transactions value $: -$12,583
Form type: 4
Date filed: 11/19/2024, 04:31 PM
Previous filing: Oct 16, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XFOR	Common Stock	Sale	-$12.6K	-31.9K	-3.11%	$0.39	994K	Nov 15, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.364 to $0.41, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.364 to $0.41, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.